Combining cell therapy development, manufacturing, and release testing with one partner reduces handoffs, streamlines logistics, and speeds therapies to patients.
Cell and gene therapy development works best when process, manufacturing, analytical and regulatory planning start together, across modalities from autologous cell therapy to viral vectors, in vivo applications and vesicles.
Fast, flexible next-generation sequencing for every cell and gene therapy modality, with multiple platforms, sub-one-week amplicon turnaround, and expert support for assay design and optimization.
Late-phase cell therapy programs require process control, automation, and characterization to improve consistency, reduce regulatory risk, and enable commercial-scale manufacturing.
An integrated platform unites synthetic DNA production with advanced therapy development and GMP manufacturing, streamlining workflows while improving speed and control.
Scale purification with confidence using a chromatography platform built for high‑titer, single‑use processes. Wide flow ranges, large columns, and automation‑ready control help reduce change.
Advanced F-PERT assays provide the sensitivity needed to identify minute levels of reverse transcriptase activity, ensuring regulatory compliance and rapid safety testing.
With 30+ years of experience in viral vector development and manufacturing, we bring unmatched expertise as your trusted CDMO for AAV. From plasmids to fill/finish and advanced analytics, we provide true end-to-end support.
